Premenstrual symptoms are one of the most common reasons people look for something to take, and one of the least-studied areas in the hydrogen literature. There is exactly one randomized controlled trial testing hydrogen-rich water against premenstrual syndrome[1]. This page covers what it did, what it found, and where the result is weaker than the headline suggests.
The trial design
The study randomized participants using a block randomization method into an intervention group and a placebo group[1]. The intervention group was asked to drink 1500 to 2000 millilitres of hydrogen-rich water daily. The placebo group drank plain water.
The dosing schedule is the most interesting design choice. Participants drank from day 16 of their menstrual cycle through to day 2 of the following cycle, and repeated that across three consecutive cycles[1]. That window is deliberate: it covers the luteal phase, which is when premenstrual symptoms occur by definition, and continues just past the onset of menstruation.
This is a different approach from most supplement trials, which use continuous daily dosing. Timing the intervention to the symptomatic phase means participants were not drinking hydrogen water during the two weeks when there would be nothing for it to affect, and it means the trial was testing a realistic use pattern rather than an artificial one.
Two instruments were used to measure outcomes. The Premenstrual Syndrome Scale, abbreviated PMSS, measures symptom severity. The short form of the World Health Organization Quality of Life Questionnaire, abbreviated WHOQOL-BREF, measures quality of life across separate domains including physical health and psychological wellbeing.
What the trial found
On the symptom scale, the intervention group had significantly lower mean PMSS scores than the control group at both the first and second follow-ups, at p less than 0.05[1]. Lower scores mean fewer or milder symptoms.
The stronger statistical finding is the group-by-time interaction for PMSS, which was significant at F equal to 10.54 and p less than 0.001[1]. An interaction term like this asks whether the two groups changed differently over the course of the study, rather than simply whether they differed at a single moment. A significant interaction is harder to produce by chance than a single between-group comparison, and it is the result that carries the most weight here.
On quality of life, the picture is more mixed, and this is where the honest reading diverges from the headline. At the first follow-up, the intervention group scored significantly higher than the control group in the Physical Health and Psychological domains of the WHOQOL-BREF, at p less than 0.05[1]. But the group-by-time interaction for WHOQOL-BREF was not significant, at p greater than 0.05.
In plain terms: the two groups differed on quality of life at one measurement point, but the trial could not demonstrate that they changed differently over time. Symptom severity passed both tests. Quality of life passed only one. The authors’ own conclusion states that hydrogen-rich water reduces premenstrual symptom severity and improves quality of life in the physical and psychological domains, and the symptom half of that conclusion rests on considerably firmer ground than the quality-of-life half.
The blinding problem with this trial
The comparison here is hydrogen-rich water against plain water. Both are clear, both are odourless, and dissolved hydrogen does not change taste in a way most people can detect, so the products themselves are hard to tell apart.
What is not hard to tell apart is the protocol. Participants knew they were in a study about hydrogen water and premenstrual symptoms, and both outcome measures are entirely self-reported questionnaires. Premenstrual symptom reporting is known to be sensitive to expectation. This is not a flaw specific to this trial so much as an unavoidable feature of studying a subjective, cyclical condition with a drinkable intervention, but it means the effect size should be treated as an upper bound rather than a precise estimate.
The volume is also worth flagging for a practical reason unrelated to blinding. Drinking 1500 to 2000 millilitres of any water daily is a meaningful hydration change for many people, and dehydration can worsen headache, fatigue and irritability, all of which appear on premenstrual symptom scales. The placebo group also drank water, which is the right control, but whether both groups were held to the same volume is the detail that determines how much of the effect could be hydration rather than hydrogen.
Why hydrogen was tested here at all
The rationale traces back to the same mechanism that underpins most hydrogen research. Hydrogen was proposed as a selective antioxidant that reduces cytotoxic oxygen radicals without interfering with the reactive species the body uses for normal signalling[2]. Non-selective antioxidants can blunt useful signalling along with harmful oxidation, and selectivity is the property that makes hydrogen theoretically interesting.
Premenstrual symptoms have been linked to inflammatory and oxidative processes that fluctuate across the cycle, which makes an anti-inflammatory or antioxidant intervention a reasonable thing to test. Separately, a 24-week trial in people with metabolic syndrome found that high-concentration hydrogen-rich water improved biomarkers of inflammation and redox homeostasis against placebo, at p less than 0.05[3], which establishes that oral hydrogen can shift inflammatory markers in humans at all.
That is a plausible chain of reasoning rather than a demonstrated mechanism. The PMS trial measured symptoms and quality of life, not inflammatory markers, so it cannot tell you whether the symptom improvement it observed happened through the pathway that motivated the study.
What one trial can and cannot establish
A single randomized controlled trial is a genuine result and a weak evidence base at the same time. It is enough to justify further study. It is not enough to establish that an effect is real, because single trials fail to replicate at a well-documented rate across all of medicine.
What would strengthen this specific finding is independent replication by a different research group, a design that measures an objective biomarker alongside the questionnaires, and matched fluid volumes between arms so hydration is fully controlled. None of that exists yet for hydrogen and premenstrual symptoms.
Practical notes if you want to try it
The trial’s dosing window is the most transferable part of the protocol: day 16 of the cycle through day 2 of the next, rather than continuously. If you are going to test this on yourself, matching the timing that was actually studied is more sensible than inventing your own schedule.
Track symptoms with a consistent instrument across at least three cycles before drawing any conclusion. Premenstrual symptom severity varies substantially cycle to cycle for reasons that have nothing to do with what you are drinking, and a single good month proves nothing. Three cycles is also what the trial used.
Severe premenstrual symptoms, and particularly premenstrual dysphoric disorder, are medical conditions with established treatments. Symptoms that interfere with work, relationships or daily function warrant a conversation with a clinician rather than a self-directed experiment, and hydrogen water is not a reason to postpone that conversation.
The bottom line
One randomized controlled trial found that hydrogen-rich water taken from day 16 of the cycle to day 2 of the next, across three cycles, significantly reduced premenstrual symptom severity, with a group-by-time interaction at p less than 0.001[1]. The quality-of-life findings were weaker: between-group differences appeared at one follow-up, but the group-by-time interaction was not significant.
It is a single unreplicated trial with entirely self-reported endpoints in a condition sensitive to expectation. That makes it the best available evidence on this question and a thin basis for confidence.
References
- The effect of hydrogen-rich water consumption on premenstrual symptoms and quality of life: a randomized controlled trial. BMC Women’s Health, 2024
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
- The Effects of 24-Week, High-Concentration Hydrogen-Rich Water on Body Composition, Blood Lipid Profiles and Inflammation Biomarkers in Men and Women with Metabolic Syndrome. Diabetes, Metabolic Syndrome and Obesity, 2020
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
